Abstract
We evaluated the safety and immunogenicity of a chimeric alphavirus vaccine candidate in mice with selective immunodeficiencies. This vaccine candidate was highly attenuated in mice with deficiencies in the B and T cell compartments, as well as in mice with deficient gamma-interferon responsiveness. However, the level of protection varied among the strains tested. Wild type mice were protected against lethal VEEV challenge. In contrast, alpha/beta (αβ) TCR-deficient mice developed lethal encephalitis following VEEV challenge, while mice deficient in gamma/delta (γδ) T cells were protected. Surprisingly, the vaccine potency was diminished by 50% in animals lacking interferon-gamma receptor alpha chain (R1)-chain and a minority of vaccinated immunoglobulin heavy chain-deficient (μMT) mice survived challenge, which suggests that neutralizing antibody may not be absolutely required for protection. Prolonged replication of encephalitic VEEV in the brain of pre-immunized mice is not lethal and adoptive transfer experiments indicate that CD3+ T cells are required for protection.
Original language | English (US) |
---|---|
Pages (from-to) | 307-323 |
Number of pages | 17 |
Journal | Virology |
Volume | 367 |
Issue number | 2 |
DOIs | |
State | Published - Oct 25 2007 |
Keywords
- Alphavirus immunity
- Pathogenesis
- Recombinant vaccines
- Venezuelan equine encephalitis virus
ASJC Scopus subject areas
- Virology